Enoseeya Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 11 Months
- Last Filing with ROC 31 Mar 2021
- Revenue Growth %
- Net Worth -38.79%
- Total Assets 347.57%
About Enoseeya Drugs
Enoseeya Drugs Private Limited (EDPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 February 2017 (Seven years and 11 months 2 days old ). Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sabyasachi Das and Santosh Dash serve as directors at the Company.
Company Details
-
Location
Thane, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24304MH2017PTC291807
-
Company No.
291807
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
28 Feb 2017
-
Date of AGM
30 Nov 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Enoseeya Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Santosh Dash
|
Managing Director | 28-Feb-2017 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Sabyasachi Das
|
Director | 29-Sep-2018 | Current |
Financial Performance of Enoseeya Drugs.
Enoseeya Drugs Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth observed a substantial decline by a decrease of 38.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Enoseeya Drugs?
Unlock access to Enoseeya Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Vastushree Properties Private LimitedSabyasachi Das is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Enoseeya Drugs?
Enoseeya Drugs has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Enoseeya Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Enoseeya Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
